Advertisement

Prevention of Type 1 Diabetes

  • Jay S. Skyler
Reference work entry
Part of the Endocrinology book series (ENDOCR)

Abstract

There is a genetic predisposition to type 1 diabetes (T1D), particularly conferred by alleles present within the major histocompatibility complex. In susceptible individuals, an environmental trigger initiates an immune response. The immune infiltration into pancreatic islets results in beta cell damage, impairment of beta cell function, and potential destruction of beta cells. Consequently, there have been a number of studies using immune intervention in an attempt to alter the natural history of the disease. These studies have been conducted both before clinical manifestations of T1D, in an attempt to prevent the evolution of the disease, and after the clinical onset of T1D, in an attempt to slow progressive loss of beta cell function. This chapter summarizes the most important clinical trials that have been conducted to date.

Keywords

Type 1 diabetes Immunotherapy Prevention 

References

  1. A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA) – DIAPREVENT. NCT00751842. www.ClinicalTrials.gov
  2. Alhadj Ali M, Liu YF, Arif S, Tatovic D, Shariff H, Gibson VB, Yusuf N, Baptista R, Eichmann M, Petrov N, Heck S, Yang JHM, Tree TIM, Pujol-Autonell I, Yeo L, Baumard LR, Stenson R, Howell A, Clark A, Boult Z, Powrie J, Adams L, Wong FS, Luzio S, Dunseath G, Green K, O’Keefe A, Bayly G, Thorogood N, Andrews R, Leech N, Joseph F, Nair S, Seal S, Cheung H, Beam C, Hills R, Peakman M, Dayan CM. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci Transl Med. 2017;9(402):pii:eaaf7779, 9 pp.CrossRefGoogle Scholar
  3. Ambery P1, Donner TW, Biswas N, Donaldson J, Parkin J, Dayan CM. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabet Med. 2014;31:399–402.CrossRefGoogle Scholar
  4. Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, Pozzilli P, for the DEFEND Investigator Group. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014;37:2746–54.CrossRefPubMedCentralGoogle Scholar
  5. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7(315)CrossRefPubMedCentralGoogle Scholar
  6. Bonifacio E, Ziegler AG, Klingensmith G, Schober E, Bingley PJ, Rottenkolber M, Theil A, Eugster A, Puff R, Peplow C, Eisenbarth G, Hasford J, Achenbach P. The pre-POINT study group. Immune efficacy of high dose oral insulin for the primary prevention of type 1 diabetes in genetically-at-risk children: the primary oral insulin therapy (pre-POINT) study, a multicenter, double-blind, randomized, placebo-controlled clinical study. JAMA. 2015;313:1541–9.CrossRefGoogle Scholar
  7. Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, Bach JF. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med. 1988;318:663–70.CrossRefGoogle Scholar
  8. Bougneres PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C, Chaussain JL, Bach JF. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes. 1990;39:1264–72.CrossRefGoogle Scholar
  9. Chase HP, Boulware D, Rodriguez H, Donaldson D, Chritton S, Rafkin LE, Krischer JP, Skyler JS, Clare-Salzler M, The Type 1 Diabetes TrialNet Nutritional Intervention to Prevent (NIP) Type 1 Diabetes Study Group. Effect of docosahexaenoic acid (DHA) supplementation on infant inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes. Pediatr Diabetes. 2015;16:271–9.CrossRefGoogle Scholar
  10. Cook JJ, Hudson I, Harrison LC, Dean B, Colman PG, Werther GA, Warne GL, Court JM. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes. 1989;38:779–83.CrossRefGoogle Scholar
  11. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simões BP, Martinez EZ, Foss MC, Burt RK, Voltarelli JC. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009;301:1573–9.CrossRefGoogle Scholar
  12. CTLA-4 Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus. ClinicalTrials.gov Identifier: NCT01773707. www.ClinicalTrials.gov
  13. D’Addio F, Valderrama Vasquez A, Ben Nasr M, Franek E, Zhu D, Li L, Ning G, Snarski E, Fiorina P. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis. Diabetes. 2014;63:3041–6.CrossRefGoogle Scholar
  14. Diabetes Prevention Trial – Type 1 Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346:1685–91.CrossRefGoogle Scholar
  15. Elding Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J, DiAPREV-IT Study Group. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: a randomized clinical trial. Pediatr Diabetes. 2017.  https://doi.org/10.1111/pedi.12611. On-line ahead of print.CrossRefGoogle Scholar
  16. European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European nicotinamide diabetes intervention trial (ENDIT): a randomized controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363:925–31.CrossRefGoogle Scholar
  17. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS, DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes. 2010;59:679–85.CrossRefGoogle Scholar
  18. Feutren G, Assan R, Karsenty G, Du Rostu H, Sirmai J, Papoz L, Vialettes B, Vexiau P, Rodier M, Lallemand A, Bach JF, For the Cyclosporin/Diabetes French Study Group. Cyclosporin increases the rate and length of remissions in insulin dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet. 1986;2(8499):119–24.CrossRefGoogle Scholar
  19. Freder1k-Study – Testing Infants for Type 1 Diabetes Risk. ClinicalTrials.gov Identifier: NCT03316261. www.ClinicalTrials.gov
  20. Gerstein HC. Cow’s milk exposure and type I diabetes mellitus. A critical overview of the clinical literature. Diabetes Care. 1994;17:13–21.CrossRefPubMedCentralGoogle Scholar
  21. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. 2011;34:2026–32.CrossRefPubMedCentralGoogle Scholar
  22. Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, the START Study Team. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: a randomized double-blind phase 2 trial. Lancet Diabetes Endocrinol. 2013;1:306–16.CrossRefPubMedCentralGoogle Scholar
  23. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS, The Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new onset type 1 diabetes. Diabetes Care. 2010;33:826–32.CrossRefPubMedCentralGoogle Scholar
  24. Gottlieb PA, Alkanani AK, Michels AW, Lewis EC, Shapiro L, Dinarello CA, Zipris D. Alpha1-antitrypsin therapy downregulates toll like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes. J Clin Endocrinol Metab. 2014;99:E1418–26.CrossRefPubMedCentralGoogle Scholar
  25. Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014;2:710–8.CrossRefPubMedCentralGoogle Scholar
  26. Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S, Stein KE, Koenig S, Daifotis AG, Herold KC, Ludvigsson J, for the Protégé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: 2-year results from the randomized, placebo-controlled protege trial. Diabetes 2013; 62:3901-3908.CrossRefPubMedCentralGoogle Scholar
  27. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Investig. 2015;2015(125):448–55.CrossRefGoogle Scholar
  28. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA, Shuster JJ, Zou B, Wasserfall CH, Posgai AL, Mathews CE, Brusko TM, Atkinson MA, Schatz DA. Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established type 1 diabetes. Diabetes. 2016;65:3765–75.CrossRefPubMedCentralGoogle Scholar
  29. Harrison LC, Colman PG, Dean B, Baxter R, Martin FI. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes. 1985;34:1306–8.CrossRefPubMedCentralGoogle Scholar
  30. Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1:295–305.CrossRefGoogle Scholar
  31. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692–8.CrossRefGoogle Scholar
  32. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54:1763–9.CrossRefPubMedCentralGoogle Scholar
  33. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, the AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013a;62:3766–74.CrossRefPubMedCentralGoogle Scholar
  34. Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013b;56:391–400.CrossRefGoogle Scholar
  35. Hummel S, Pflüger M, Hummel M, Bonifacio E, Ziegler AG. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care. 2011;34:1301–5.CrossRefPubMedCentralGoogle Scholar
  36. Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus. ClinicalTrials.gov Identifier: NCT03428945. www.ClinicalTrials.gov
  37. Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38:1964–74.CrossRefPubMedCentralGoogle Scholar
  38. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352:2598–608.CrossRefGoogle Scholar
  39. Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, Vandemeulebroucke E, Van de Velde U, Crenier L, De Block C, Candon S, Waldmann H, Ziegler AG, Chatenoud L, Pipeleers D. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010;53:614–23.CrossRefGoogle Scholar
  40. Knip M, Virtanen SM, Seppä K, Ilonen J, Savilahti E, Vaarala O, Reunanen A, Teramo K, Hämäläinen AM, Paronen J, Dosch HM, Hakulinen T, Akerblom HK, Finnish TRIGR Study Group. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med. 2010;363:1900–8.CrossRefPubMedCentralGoogle Scholar
  41. Knip M, Åkerblom HK, Becker D, Dosch HM, Dupre J, Fraser W, Howard N, Ilonen J, Krischer JP, Kordonouri O, Lawson ML, Palmer JP, Savilahti E, Vaarala O, Virtanen SM, TRIGR Study Group. Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial. JAMA. 2014;311:2279–87.CrossRefPubMedCentralGoogle Scholar
  42. Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, Kolb H. The deutsche nicotinamide intervention study: an attempt to prevent type 1 diabetes. DENIS group. Diabetes. 1998;47:980–4.CrossRefGoogle Scholar
  43. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008;359:1909–20.CrossRefGoogle Scholar
  44. Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, Veeze HJ, Palmer J. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med. 2012;366:433–42.CrossRefGoogle Scholar
  45. Malmegrim KC, de Azevedo JT, Arruda LC, Abreu JR, Couri CE, de Oliveira GL, Palma PV, Scortegagna GT, Stracieri AB, Moraes DA, Dias JB, Pieroni F, Cunha R, Guilherme L, Santos NM8, Foss MC, Covas DT, Burt RK, Simões BP, Voltarelli JC, Roep BO, Oliveira MC. Immunological Balance Is Associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes. Front Immunol 2017; 8:167.Google Scholar
  46. Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, Quattrin T. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care. 2009;32:1244–9.CrossRefPubMedCentralGoogle Scholar
  47. Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes. ClinicalTrials.gov Identifier: NCT03396484. www.ClinicalTrials.gov
  48. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett D, Wilson DM, Skyler JS, The Type 1 Diabetes TrialNet Canakinumab Study Group, Pickersgill L, de Koning E, Ziegler A-G, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T, on behalf of the AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicenter, randomized double-masked, placebo-controlled trials. Lancet. 2013;381:1905–15.CrossRefGoogle Scholar
  49. Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipilä JI, Haavisto L, Siltala M, Tuominen J, Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008;372:1746–55.CrossRefGoogle Scholar
  50. Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP, Schatz D, Eisenbarth G. Diabetes prevention trial-type 1 study group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care. 2009;32:2269–74.CrossRefPubMedCentralGoogle Scholar
  51. Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, Tchao N, Sayre P, Bianchine P. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun. 2010;34:408–15.CrossRefPubMedCentralGoogle Scholar
  52. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Skyler JS, The Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised double-blind, placebo-controlled trial. Lancet. 2011;378:412–9.CrossRefPubMedCentralGoogle Scholar
  53. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Skyler JS, The Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up one year after cessation of treatment. Diabetes Care. 2014;37:1069–75.CrossRefPubMedCentralGoogle Scholar
  54. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS, The Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion and preservation of Beta-cell function. N Engl J Med. 2009;361:2143–52.CrossRefGoogle Scholar
  55. Pescovitz MD, Greenbaum CJ, Bundy BN, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Skyler JS, The Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and Beta-cell function: two-year results. Diabetes Care. 2014;37:453–9.CrossRefPubMedCentralGoogle Scholar
  56. PINIT Study: Primary Intranasal Insulin Trial. ClinicalTrials.gov Identifier: NCT03182322. www.ClinicalTrials.gov
  57. Pozzilli P, Raz I, Peled D, Elias D, Avron A, Tamir M, Eren R, Dagan S, Cohen IR. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed-meal. Diabetes Care. 2014;37:1384–91. Statement of Retraction. Diabetes Care 2015; 38:179.CrossRefGoogle Scholar
  58. Pre-POINT Early Study. ClinicalTrials.gov Identifier: NCT02547519. www.ClinicalTrials.gov
  59. Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies (DiAPREV-IT2). ClinicalTrials.gov Identifier: NCT02387164. www.ClinicalTrials.gov
  60. Raab J, Haupt F, Scholz M, Matzke C, Warncke K, Lange K, Assfalg R, Weininger K, Wittich S, Löbner S, Beyerlein A, Nennstiel-Ratzel U, Lang M, Laub O, Dunstheimer D, Bonifacio E, Achenbach P, Winkler C, Ziegler AG, Fr1da Study Group. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open. 2016;6(5):e011144.CrossRefPubMedCentralGoogle Scholar
  61. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. ß-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet. 2001;358:1749–53.CrossRefPubMedCentralGoogle Scholar
  62. Raz I, Ziegler AG, Linn T, Schernthaner G, Bonnici F, Distiller LA, Giordano C, Giorgino F, de Vries L, Mauricio D, ProchaÅLzka V, Wainstein J, Elias D, Avron A, Tamir M, Eren R, Peled D, Dagan S, Cohen IR, Pozzilli P, The DIA-AID 1 writing group. Treatment of recent onset type 1 diabetes patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. Diabetes Care. 2014;37:1392–400. Statement of Retraction. Diabetes Care 2015; 38:178.CrossRefPubMedCentralGoogle Scholar
  63. Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR, The T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013;1:284–94.CrossRefPubMedCentralGoogle Scholar
  64. Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Investig. 2015;125:3285–96.CrossRefPubMedCentralGoogle Scholar
  65. Roep BO, Solvason N, Gottlieb PA, Abreu JR, Harrison LC, Eisenbarth GS, Yu L, Leviten M, Hagopian WA, Buse JB, von Herrath M, Quan J, King RS, Robinson WH, Utz PJ, Garren H, BHT-3021 Investigators, Steinman L. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. Sci Transl Med. 2013;5(191):191ra82.CrossRefPubMedCentralGoogle Scholar
  66. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG, Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378:487-497.CrossRefGoogle Scholar
  67. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med. 1988;319:599–604.CrossRefPubMedCentralGoogle Scholar
  68. Skyler JS. Immune intervention studies in insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1987;3:1017–35.CrossRefPubMedCentralGoogle Scholar
  69. Skyler JS. Primary and secondary prevention of type 1 diabetes. Diabet Med. 2013a;30:161–9.CrossRefPubMedCentralGoogle Scholar
  70. Skyler JS. The compelling case for anti-CD3 in type 1 diabetes. Diabetes. 2013b;62:3656–7.CrossRefPubMedCentralGoogle Scholar
  71. Skyler JS. The prevention & reversal of type 1 diabetes – past challenges & future opportunities. Diabetes Care. 2015;38:997–1007.CrossRefGoogle Scholar
  72. Skyler JS, Marks JB. Immune intervention in type I diabetes mellitus. Diabetes Rev. 1993;1:15–42.Google Scholar
  73. Skyler JS, Rabinovitch A, The Miami Cyclosporine Diabetes Study Group. Cyclosporine in recent onset type I diabetes mellitus: effects on islet beta cell function. J Diabetes Complicat. 1992;6:77–88.CrossRefGoogle Scholar
  74. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E, Diabetes Prevention Trial – Type 1 Diabetes Study Group. Effects of oral insulin in relatives of patients with type 1 diabetes mellitus. Diabetes Care. 2005;28:1068–76.CrossRefGoogle Scholar
  75. Skyler JS, Krischer JP, Becker DJ, Rewers M. Prevention of type 1 diabetes, Chapter 37. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, KMV N, Rewers M, Fradkin JE, editors. Diabetes in America. 3rd ed. Bethesda: National Institutes of Health, NIH Pub No. 17-1468; 2017. p. 37.1–21.Google Scholar
  76. Sosenko JM, Skyler JS, Herold KC, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the diabetes prevention trial-type 1. Diabetes. 2012;61:1331–7.CrossRefPubMedCentralGoogle Scholar
  77. Teplizumab for Prevention of Type 1 Diabetes in Relatives “At-Risk”. ClinicalTrials.gov Identifier: NCT01030861. www.ClinicalTrials.gov
  78. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes. 1988;37:1574–82.CrossRefGoogle Scholar
  79. Thrower SL, James L, Hall W, Green KM, Arif S, Allen JS, Van-Krinks C, Lozanoska-Ochser B, Marquesini L, Brown S, Wong FS, Dayan CM, Peakman M. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study. Clin Exp Immunol. 2009;155:156–65.CrossRefPubMedCentralGoogle Scholar
  80. Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes (INIT II). ClinicalTrials.gov Identifier: NCT00336674. www.ClinicalTrials.gov
  81. TRIGR Study Group, Akerblom HK, Krischer J, Virtanen SM, Berseth C, Becker D, Dupré J, Ilonen J, Trucco M, Savilahti E, Koski K, Pajakkala E, Fransiscus M, Lough G, Bradley B, Koski M, Knip M. The trial to reduce IDDM in the genetically at risk (TRIGR) study: recruitment, intervention and follow-up. Diabetologia. 2011;54:627–33.CrossRefGoogle Scholar
  82. Vaarala O, Ilonen J, Ruohtula T, Pesola J, Virtanen SM, Härkönen T, Koski M, Kallioinen H, Tossavainen O, Poussa T, Järvenpää AL, Komulainen J, Lounamaa R, Akerblom HK, Knip M. Removal of bovine insulin from cow’s milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch Pediatr Adolesc Med. 2012;166:608–14.CrossRefGoogle Scholar
  83. Vandemeulebroucke E, Gorus F, Decochez K, Weets I, Keymeulen B, De Block C, Tits J, Pipeleers D, Mathieu C, The Belgian Diabetes Registry. Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab. 2009;35:319–27.CrossRefGoogle Scholar
  84. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simões BP, Foss MC, Squiers E, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297:1568–76.CrossRefGoogle Scholar
  85. Voltarelli JC, Martinez ED, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. Author’s reply. JAMA. 2009;302:624–5.CrossRefGoogle Scholar
  86. Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R. NBI-6024 study group. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care. 2009;32:2036–40.CrossRefPubMedCentralGoogle Scholar
  87. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Raskin P, Rodriguez H, Russell WE, Schatz D, Wilson DM, Skyler JS, The Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011;378:319–27.CrossRefPubMedCentralGoogle Scholar
  88. Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA. 2017;318:1891–902.CrossRefPubMedCentralGoogle Scholar
  89. Writing Group for the TRIGR Study Group, Knip M, Åkerblom HK, Al Taji E, Becker D, Bruining J, Castano L, Danne T, de Beaufort C, Dosch HM, Dupre J, Fraser WD, Howard N, Ilonen J, Konrad D, Kordonouri O, Krischer JP, Lawson ML, Ludvigsson J, Madacsy L, Mahon JL, Ormisson A, Palmer JP, Pozzilli P, Savilahti E, Serrano-Rios M, Songini M, Taback S, Vaarala O, White NH, Virtanen SM, Wasikowa R. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes: the TRIGR randomized clinical trial. JAMA. 2018;319:38–48.CrossRefPubMedCentralGoogle Scholar
  90. Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity. 2010;32:468–78.CrossRefPubMedCentralGoogle Scholar
  91. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309:2473–9.CrossRefPubMedCentralGoogle Scholar
  92. Ziegler AG, Danne T, Dunger DB, Berner R, Puff R, Kiess W, Agiostratidou G, Todd JA, Bonifacio E. Primary prevention of beta-cell autoimmunity and type 1 diabetes – the global platform for the prevention of autoimmune diabetes (GPPAD) perspectives. Mol Metab. 2016;5:255–62.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Diabetes Research InstituteUniversity of MiamiMiamiUSA

Personalised recommendations